WO2004011014A1 - Matiere pouvant etre ingeree destinee au traitement des pathologies du systeme digestif humain - Google Patents

Matiere pouvant etre ingeree destinee au traitement des pathologies du systeme digestif humain Download PDF

Info

Publication number
WO2004011014A1
WO2004011014A1 PCT/GB2003/003127 GB0303127W WO2004011014A1 WO 2004011014 A1 WO2004011014 A1 WO 2004011014A1 GB 0303127 W GB0303127 W GB 0303127W WO 2004011014 A1 WO2004011014 A1 WO 2004011014A1
Authority
WO
WIPO (PCT)
Prior art keywords
ingestible material
disease
ingestible
inflammation
bacteria
Prior art date
Application number
PCT/GB2003/003127
Other languages
English (en)
Inventor
Seth Kendall
Original Assignee
Seth Kendall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0217290A external-priority patent/GB0217290D0/en
Priority claimed from GB0304135A external-priority patent/GB0304135D0/en
Priority claimed from GB0312302A external-priority patent/GB0312302D0/en
Application filed by Seth Kendall filed Critical Seth Kendall
Priority to AU2003281757A priority Critical patent/AU2003281757A1/en
Publication of WO2004011014A1 publication Critical patent/WO2004011014A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/115—Cereal fibre products, e.g. bran, husk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Definitions

  • This invention relates to an ingestible material for the treatment of disease in the human digestive system, for use particularly, but not exclusively as a medical or cosmetic treatment for Rosacea.
  • Rosacea is a common facial dermatosis. Its primary symptom is an increase in the sensitivity of the facial vasculature. Sufferers can experience facial flushing around the cheeks, chin, nose, forehead, neck and occasionally the upper chest. It is common for the eyes to be affected and in the worst cases this can result in irreversible injury to the sufferer's vision.
  • the disease is generally progressive and can lead to a permanent erythema (redness) across affected areas and the development of telangiectasia (thread veins). Further, sufferers can experience papules and pustules, and in severe cases a condition known as rhinophyma may develop, where the tissue of the nose becomes inflamed and overgrown leading to disfigurement. Rosacea usually begins in individuals aged between 30 and 50 years with a lighter complexion, although anyone can suffer from it at any age.
  • Rosacea The cause of Rosacea is currently unknown. The development of symptoms can often be traced to a period of acute, or repeated, irritation of the facial skin, for example through excessive exposure to sunlight or through the use of topical facial preparations, for example acne medications or cosmetic treatments. However, frequently the onset of symptoms is gradual and no clearly definable event marks the initiation of the disease. Once the onset of the disease has occurred and the facial vasculature has become hypersensitised, any number or combination of factors may provoke a worsening of symptoms, including sunlight, wind, cold, heat, physical exertion, humidity or the consumption of certain foods or medications. Rosacea has been associated with disorders of the digestive system but this association has never been satisfactorily explained.
  • the papulo-pustular element of Rosacea has been successfully treated with retinoids, however, these do not address the underlying vascular disorder, and can exacerbate the vascular symptoms.
  • Rosacea is caused by digestive system disorders.
  • the plasma kallikrein-kinin system can be activated in response to inflammatory reactions in the digestive system.
  • Such inflammatory reactions are varied and can be extremely mild in some cases and may not present local symptoms. They can occur in many regions of the digestive tract especially in the stomach, the small and the large intestine.
  • Rosacea Various digestive disorders have already been connected to Rosacea, and typical examples include: Helicobacter Pylon infection. Infection by this bacterium has been associated with Rosacea, and there have been a small number of striking examples where Rosacea has been cured by its eradication. However, it has also been demonstrated that eradication of H. Pylon in the majority of Rosacea sufferers only provides some symptomatic improvement at best, and is unlikely to cure the disease. It has also been demonstrated that most Rosacea sufferers are not infected with H. Pylori, which would indicate that H. Pylori cannot be the sole cause of Rosacea.
  • Rosacea cases are caused by a reaction in response to the presence of luminal bacteria in the intestines.
  • Luminal bacteria feed on partially digested food, frequently undigested carbohydrates.
  • Bacteria are commonly resident in human intestines, especially within the colon. However, bacteria can proliferate, both within the colon and elsewhere, if there is sufficient quantity and type of fermentable material present in the intestines and enough time for the bacteria to consume it.
  • This reaction may be caused by a particular persistent pathogen or by the endotoxins produced by a particular persistent pathogen, by a defect in the mucosal barrier which leads to increased exposure to the bacteria or their endotoxins, or by an overly aggressive immune response to the resident luminal bacteria or their endotoxins.
  • the inflammation and/or activation of the plasma kallikrein-kinin system can be caused by any one or any combination of these circumstances, and the response is individual to the patient. Some individuals may be able to tolerate a quantity of bacteria or their endotoxins greater than others without suffering any detectable reaction.
  • bradykinin When bradykinin binds to receptors on afferent neurons, it can stimulate and sensitise such neurons, provoking the release of a number of proinflammatory substances and in particular the neuropeptides substance P and calcitonin gene- related peptide. These substances, in turn, can act on target cells in the periphery such as mast cells, immune cells and vascular smooth muscle causing inflammation characterised by vasodilation, plasma extravasation, edema and hypersensitivity. Inflammatory symptoms resulting from the release of substances by afferent neurons is referred to as neurogenic inflammation. The vascular symptoms of Rosacea are a consequence of neurogenic inflammation.
  • the present invention is intended to overcome some of these problems by addressing the proliferation of luminal bacteria in the digestive tract.
  • an ⁇ ngestible material adapted to reduce and/or prevent disease in a human digestive system by reducing and/or maintaining the quantity of bacteria which causes disease in said human digestive system to a level below that required to cause the disease, is provided with a composition and/or physical properties adapted to stimulate peristaltic contractions in the intestines, and which is provided with a texture and viscosity adapted to pass through the digestive tract in less than 35 hours.
  • the material is adapted to reduce and/or prevent inflammation in the human digestive system by reducing and/or maintaining the quantity of bacteria which causes the inflammation in said human digestive system to a level below that required to cause the inflammation.
  • the material is adapted to reduce and/or prevent exposure to luminal bacteria and/or bacterial endotoxins and/or the products of bacterial fermentation in the intestines which causes activation of the plasma kallikrein-kinin system, by reducing and/or maintaining the quantity of bacteria within the human digestive tract which reduces exposure to luminal bacteria and/or bacterial endotoxins and/or products of bacterial fermentation to a level below that required to cause activation of the plasma kallikrein-kinin system.
  • the ingestible material is adapted to reduce and/or maintain the quantity of luminal bacteria in the human digestive system, and in particular the small intestine, which activates the kallikrein-kinin system which leads to the production of bradykinin and/or related kinins, which stimulates and/or sensitizes afferent neurons, which leads to the occurrence of Rosacea symptoms.
  • the present invention can also be used to reduce and/or maintain the quantity of bacteria in the human digestive tract which causes disease and/or inflammation, which can be used to treat the symptoms of other diseases and disorders.
  • These symptoms can result either from activation of the plasma kallikrein-kinin system leading to hypersensitisation of afferent neurons or these symptoms can result from other mechanisms of disease resulting from luminal bacteria in the intestines.
  • Such disorders may include abdominal bloating, acne or acneform eruptions (which includes acne vulgaris), Alzheimer's disease, affective disorders, alopecia, anaphylaxis, ankylosing spondilitis and other spondyloarthropathies, anxiety disorders, arthritis, asthma, attention deficit disorder (ADD & ADHD), attentional disorders, atypical face pain, autism (including all autistic spectrum disorders e.g.
  • Asperger's syndrome Pervasive Develpmental Disorder, Rett's Syndrome etc.
  • autoimmune disorders including hypothyroidism, scleroderma, lupus, polymyositis, vasculitis
  • blushing body dysmorphic disorder, bruxism, cataplexy, chronic pain, chronic fatigue, chronic pelvic pain syndromes (which includes interstitial cystitis), colonic cancer, concentration impairment, Crohn's disease, dandruff, depression, dizziness, eating disorders (bulimia, anorexia, binging), emesis, fibromyalgia, Gulf War syndrome, hypersomnia, hypothyroidism, impulse-control disorders, insomnia, intermittent explosive disorder, irritable bowel syndrome, kleptomania, memory impairment, migraine/severe headache, mood disorders, morning fatigue, motion sickness, multiple chemical sensitivity, myofascial pain syndrome, narcolepsy, obesity, obsessive-compulsive disorder, pancreatitis, panic disorder
  • Patent US6241993 sick building syndrome, sinusitis, social phobia, somatoform disorders, substance abuse and addiction (including alcoholism), temporo-mandibular disorders, tinnitus, tonsillitis, Tourette's disorder, trichotillomania, ulcerative colitis, a reduced level of restorative sleep, various other neuropsychiatric disorders and various other cognitive dysfunctions and any other diseases belonging to the affective spectrum disorder.
  • the ingestible material may be adapted to reduce and/or maintain the quantity of luminal bacteria in the human digestive system which prevents or reduces activation of the plasma kallikrein-kinin system and the production of bradykinin.
  • the transit time of food through the digestive tract is significantly reduced.
  • the ingestible material results in a transit time of food of between 24 and 35 hours. If the transit time of food through the digestive tract is reduced to this length of time the luminal bacterial populations are decreased and their capacity to cause disease and/or inflammation in the human digestive tract is reduced or abolished, and the above described sequence leading to the occurrence of Rosacea symptoms is inhibited.
  • the ingestible material stimulates peristaltic contractions in the walls of the intestines due to the size and texture of its particles. Further, the size and texture of the particles may be further adapted to cause no injury to the intestinal walls.
  • the material can be non-soluble in water, and be provided with the property of retaining water or other liquids. When mixed with water or another liquid, the material can be provided with the optimum viscosity to assist its passage through the digestive tract.
  • the material may possess or may be used in conjunction with other materials or liquids that possess lubricative properties which further assist its passage through the digestive tract by reducing its impedance due to friction.
  • the indigestible material may be coarse wheat bran, or be provided with similar physical properties to those of coarse wheat bran.
  • the material is adapted to cause no allergic or irritative reaction to the walls of the digestive tract. In a further embodiment the material is adapted to reduce any allergic or irritative reaction in the walls of the digestive tract.
  • the material may also be unfermentable by bacteria, or may be adapted to reduce any bacterially fermentable properties, as this will further prevent occurrences of luminal bacteria.
  • the material may also be selectively fermentable by bacteria, having fermentable properties that favour those bacterial species that are considered to be less capable of causing disease and/or inflammation. This may modify the luminal environment of the digestive tract because the competition between species may result in a hostile environment for those bacteria considered to be responsible for causing the disease and/or inflammation.
  • the material may have, or my be adapted to have when ingested, a reduced pH level which reduces the pH level in the intestines and/or the stomach, which further inhibits the growth and/or proliferation of luminal bacteria.
  • the ingestible material may possess, or may be used in combination with another material which possesses antibacterial properties.
  • the treatment material will be capable of modifying the environment within the digestive tract to make it more hostile to the growth and/or survival of bacteria.
  • the ingestible material is coarse wheat bran with gluten and possibly other protein reduced/removed. This can be done in any known way, for example the coarse wheat bran may be hydrolysed to achieve this end.
  • the ingestible material can comprise finely shredded 100% pure cotton paper, which is greater than 185gm per square metre.
  • the cotton can preferably be boiled in water for 20 minutes, drained and then mixed with a carrier food, for example porridge or rice pudding.
  • the invention also includes a method of reducing and/or preventing disease and/or inflammation in a human digestive system, comprising the consumption of an ingestible material provided with a composition and/or physical properties adapted to stimulate peristaltic contractions in the intestines, and which is provided with a texture and viscosity adapted to pass through the digestive tract in less than 35 hours.
  • the invention further includes a method as defined above, which is combined with a general diet consisting of reduced carbohydrates and in particular carbohydrates that are not monosaccharide.
  • an ingestible material provided with a composition and/or physical properties adapted to stimulate peristaltic contractions in the intestines, and which is provided with a texture and viscosity adapted to pass through the digestive tract in less than 35 hours is used for the manufacture of a medicament for reducing and/or preventing disease and/or inflammation in the human digestive system.
  • the ingestible material is used for the manufacture of a medicament for the treatment of disease and/or inflammation in the human digestive system which causes activation of the kallikrein-kinin system which leads to the production of bradykinin which sensitises afferent neurons, which leads to one or more Rosacea symptoms.
  • an ingestible material adapted to reduce and/or prevent disease and/or inflammation in a human digestive system by reducing and/or maintaining the quantity of bacteria which causes the disease and/or inflammation in said human digestive system to a level below that required to cause the disease and/or inflammation comprises a carrier substance and a material provided with a composition and/or physical properties adapted to stimulate peristaltic contractions in the intestines, and which is provided with a texture and viscosity adapted to pass through the digestive tract in less than 35 hours.
  • the carrier liquid is water and the ingestible material comprises water and coarse wheat bran, or a material provided with the physical properties of coarse wheat bran.
  • the invention can be performed in various ways, but three embodiments will now be described by way of example.
  • An ingestible material adapted to reduce and/or prevent disease and/or inflammation in a human digestive system which leads to activation of the plasma kallikrein-kinin system by reducing and/or maintaining the quantity of bacteria which cause the disease and/or inflammation in said human digestive system to a level below that required to cause the disease and/or inflammation comprises coarse wheat bran mixed with warm water.
  • the gluten in the wheat bran caused an allergic or intolerant reaction in the intestines, in particular the upper small intestine, after a number of weeks of the treatment. This led to inflammation in the digestive tract and activation of the kallikrein-kinin system, leading to the subsequent chain reaction as described above leading to a worsening of Rosacea symptoms.
  • an ingestible material adapted to reduce and/or prevent disease and/or inflammation in a human digestive system which causes activation of the kallikrein-kinin system by reducing and/or maintaining the quantity of bacteria which causes the disease and/or inflammation in said human digestive system to a level below that required to cause the disease and/or inflammation, comprises hydrolysed coarse wheat bran mixed with warm water.
  • the process of hydrolysation is known, and involves boiling the subject material in acid for several hours. The result is that most of the protein including the gluten content in wheat bran is destroyed, rendering it far less allergenic.
  • an ingestible material adapted to reduce and/or prevent disease and/or inflammation in a human digestive system which causes activation of the kallikrein-kinin system by reducing and/or maintaining the quantity of bacteria which causes the disease and/or inflammation in said human digestive system to a level below that required to cause the disease and/or inflammation, comprises finely shredded 100% pure cotton paper, which is greater than 185gm per square metre.
  • the cotton is boiled in water for 20 minutes, drained and then mixed with a carrier food, for example porridge or rice pudding. Once prepared the cotton is essentially pure fibrous flakes of cellulous, which are hypoallergenic.
  • an ingestible material which when consumed after food leads to a reduction of the transit time of the food through the digestive tract, and a reduction in the chance of luminal bacteria initiating an inflammatory reaction in the digestive tract and activation of the plasma kallikrein-kinin system, which subsequently reduces the symptoms of Rosacea.
  • the invention also includes a method of treating disease and/or inflammation in the human digestive system which causes activation of the kallikrein-kinin system, comprising the consumption of an ingestible material adapted to reduce and/or prevent disease and/or inflammation in a human digestive system by reducing and/or maintaining the quantity of bacteria which causes the disease and/or inflammation in said human digestive system to a level below that required to cause the disease and/or inflammation.
  • the method comprises the following steps:
  • the method of treating disease and/or inflammation as described above also includes using coarse wheat bran with reduced levels of, or no, protein and gluten present in it.
  • the present invention can also be used in the treatment and/or prevention of diseases or conditions which are caused by disease and/or inflammation in the intestines induced by intestinal luminal bacteria and/or their endotoxins and/or the products of their fermentation.
  • Such disorders may include abdominal bloating, acne or acneform eruptions (which includes acne vulgaris), Alzheimer's disease, affective disorders, alopecia, anaphylaxis, ankylosing spondilitis and other spondyloarthropathies, anxiety disorders, arthritis, asthma, attention deficit disorder (ADD & ADHD), attentional disorders, atypical face pain, autism (including all autistic spectrum disorders e.g.
  • Asperger's syndrome Pervasive Develpmental Disorder, Rett's Syndrome etc.
  • autoimmune disorders including hypothyroidism, scleroderma, lupus, polymyositis, vasculitis
  • blushing body dysmorphic disorder, bruxism, cataplexy, chronic pain, chronic fatigue, chronic pelvic pain syndromes (which includes interstitial cystitis), colonic cancer, concentration impairment, Crohn's disease, dandruff, depression, dizziness, eating disorders (bulimia, anorexia, binging), emesis, fibromyalgia, Gulf War syndrome, hypersomnia, hypothyroidism, impulse-control disorders, insomnia, intermittent explosive disorder, irritable bowel syndrome, kleptomania, memory impairment, migraine/severe headache, mood disorders, morning fatigue, motion sickness, multiple chemical sensitivity, myofascial pain syndrome, narcolepsy, obesity, obsessive-compulsive disorder, pancreatitis, panic disorder
  • Patent US6241993 sick building syndrome, sinusitis, social phobia, somatoform disorders, substance abuse and addiction (including alcoholism), temporo-mandibular disorders, tinnitus, tonsillitis, Tourette's disorder, trichotillomania, ulcerative colitis, a reduced level of restorative sleep, various other neuropsychiatric disorders and various other cognitive dysfunctions and any other diseases belonging to the affective spectrum disorder.
  • the present invention is intended to prevent and/or reduce any disease in the human digestive system, it can therefore also be used pro-actively to promote or maintain the general good health of the digestive system and/or the prevention of any of the fore-mentioned diseases that can be caused by the presence of luminal bacteria in the digestive tract.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une matière pouvant être ingérée conçue pour réduire et/ou prévenir les pathologies du système digestif humain par réduction et/ou maintien de la quantité de bactérie provoquant des pathologies dans le système digestif humain à un niveau inférieur à celui qui provoque des pathologies. Cette matière est pourvue d'une composition et/ou de propriétés physiques conçues pour stimuler les contractions péristaltiques dans les intestins, et est dotée d'une texture et d'une viscosité conçues pour traverser le tube digestif en moins de 35 heures.
PCT/GB2003/003127 2002-07-25 2003-07-18 Matiere pouvant etre ingeree destinee au traitement des pathologies du systeme digestif humain WO2004011014A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003281757A AU2003281757A1 (en) 2002-07-25 2003-07-18 Ingestible material for the treatment of disease in the human digestive system

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0217290.6 2002-07-25
GB0217290A GB0217290D0 (en) 2002-07-25 2002-07-25 Ingestible material for the treatment of rosacea
GB0304135A GB0304135D0 (en) 2003-02-24 2003-02-24 Ingestible material for the treatment of psoriasis
GB0304135.7 2003-02-24
GB0312302A GB0312302D0 (en) 2003-05-29 2003-05-29 Ingestible material for the treatment of psoriasis
GB0312302.3 2003-05-29

Publications (1)

Publication Number Publication Date
WO2004011014A1 true WO2004011014A1 (fr) 2004-02-05

Family

ID=31191731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/003127 WO2004011014A1 (fr) 2002-07-25 2003-07-18 Matiere pouvant etre ingeree destinee au traitement des pathologies du systeme digestif humain

Country Status (2)

Country Link
AU (1) AU2003281757A1 (fr)
WO (1) WO2004011014A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103783528A (zh) * 2014-02-17 2014-05-14 秦胜林 一种治疗乳腺囊性增生症的药食同源食品及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526800A (en) * 1980-04-26 1985-07-02 Howard Alan N Cereal snackfoods and compositions and methods for making the same
JPH0567A (ja) * 1991-06-20 1993-01-08 Towa Kasei Kogyo Kk カルシウム及び食物繊維含有飲食物とその製造方法
JPH05163157A (ja) * 1991-12-18 1993-06-29 Sakai Chem Ind Co Ltd アルギン酸・トロンビン固定化物、その製法および止血剤
EP0586933A1 (fr) * 1992-09-08 1994-03-16 Nippon Tensaiseito Kabushiki Kaisha Agents pour supprimer ou diminuer les lipides sanguines
JPH11246422A (ja) * 1997-12-26 1999-09-14 Yakult Honsha Co Ltd 消化管内環境改善剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526800A (en) * 1980-04-26 1985-07-02 Howard Alan N Cereal snackfoods and compositions and methods for making the same
JPH0567A (ja) * 1991-06-20 1993-01-08 Towa Kasei Kogyo Kk カルシウム及び食物繊維含有飲食物とその製造方法
JPH05163157A (ja) * 1991-12-18 1993-06-29 Sakai Chem Ind Co Ltd アルギン酸・トロンビン固定化物、その製法および止血剤
EP0586933A1 (fr) * 1992-09-08 1994-03-16 Nippon Tensaiseito Kabushiki Kaisha Agents pour supprimer ou diminuer les lipides sanguines
JPH11246422A (ja) * 1997-12-26 1999-09-14 Yakult Honsha Co Ltd 消化管内環境改善剤

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FOLINO MARISA ET AL: "Dietary fibers differ in their effects on large bowel epithelial proliferation and fecal fermentation-dependent events in rats.", JOURNAL OF NUTRITION, vol. 125, no. 6, 1995, pages 1521 - 1528, XP009018240, ISSN: 0022-3166 *
MORITA T ET AL: "Dietary fiber and fat-derivatives prevent mineral oil toxicity in rats by the same mechanism", JOURNAL OF NUTRITION 1993 UNITED STATES, vol. 123, no. 9, 1993, pages 1575 - 1585, XP009018294, ISSN: 0022-3166 *
PATENT ABSTRACTS OF JAPAN vol. 017, no. 247 (C - 1059) 18 May 1993 (1993-05-18) *
PATENT ABSTRACTS OF JAPAN vol. 017, no. 567 (C - 1120) 14 October 1993 (1993-10-14) *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 14 22 December 1999 (1999-12-22) *
TAKEDA H ET AL: "EFFECT OF PARTICLE SIZE OF DIETARY FIBER ON ITS SETTLING VOLUME IN WATER AND PROTECTIVE ACTIVITY AGAINST AMARANTH FOOD RED NO. 2 TOXICITY IN RATS", NIPPON NOGEIKAGAKU KAISHI, vol. 65, no. 2, 1991, pages 171 - 176, XP009018295, ISSN: 0002-1407 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103783528A (zh) * 2014-02-17 2014-05-14 秦胜林 一种治疗乳腺囊性增生症的药食同源食品及其制备方法

Also Published As

Publication number Publication date
AU2003281757A1 (en) 2004-02-16

Similar Documents

Publication Publication Date Title
Miller Symbiosis between laboratory and clinic
Bartram Bartram's encyclopedia of herbal medicine
WO2004011014A1 (fr) Matiere pouvant etre ingeree destinee au traitement des pathologies du systeme digestif humain
CN106659754A (zh) 膳食补充剂
RU2070050C1 (ru) Средство для стимуляции моторно-эвакуаторной функции кишечника у детей
CN111973636A (zh) 一种肛肠凝胶及其制备方法
Shirah The value of Mountain Sidr Honey in treating and controlling chronic constipation: A Prospective comparative study between Ziziphus honey and Lactulose in 1000 Saudi Arabian patients
Klajn-Laslo Chronic candidiasis-pathogenesis, symptoms, diagnosis and treatment
Stibal ThetaHealing Diseases and Disorders
Ivakhnenko et al. THE DEMODEX SOLUTION: The Ultimate 90 Day Treatment Program to Eliminate Demodex Mite, Heal Skin Troubles, & Tackle Inflammation Naturally.
Heidari THERAPEUTIC EFFECT OF APPLES IN NARRATIONS WITH EMPHASIS ON NEW MEDICAL FINDINGS.
RU2365376C2 (ru) Набор для лечения дисбактериоза и способ лечения
Perera et al. Evaluation of the effect and efficacy of selected herbal formula from ola leaves manuscript in the management of migraine
Qiyomova THE EFFECT OF FERULA EXTRACT ON THE ACTIVITY OF DIGESTIVE ENZYMES
Klaina Honey In The Quran And Sunnah: Exploring Its Medicinal Properties
Day Prepare for an EMERGENCY now
Whiting Systemic Candida & Yeast Infections
Spray et al. General Health
RU2178700C1 (ru) Способ лечения синдрома раздраженной кишки
Honda Reverse Gut Diseases Naturally: Cures for Crohn's Disease, Ulcerative Colitis, Celiac Disease, IBS, and More
Chen Principle Based Medicine
Margaritti et al. Gemotherapy, an alternative to treatment of animal disorders. Actual trends on the pharmaceutical market.
RU2161978C2 (ru) Способ лечения аллергических заболеваний у детей
ECONOMY GUT HEALTH: FOCUSING ON OUR INNER ECONOMY
RU2239425C1 (ru) Способ лечения колибактериоза и сальмонеллеза у поросят

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP